Omniscient Announces FDA Clearance of New MRI-based Functional Brain Analysis Technology


Omniscient announced FDA clearance for new functional brain mapping software, ‘Quicktome FC (Functional Connectome)’. This software has the capability to uncover the distinct connectivity patterns of an individual’s brain in a single scan.

The application of connectomics in the study of brain disorders has the potential to revolutionise the understanding of brain and how it functions. Connectomics focuses on mapping the intricate network of connections within the brain, providing insights into how different regions communicate and work together.

Integrating resting-state functional MRI (rs-fMRI) technology into Omniscient’s Quicktome platform can offer a valuable tool for assessing and treating neurological disorders. Its non- invasive nature, resting-state assessment capability, functional connectivity mapping, treatment guidance potential, and visualisation features make it a promising addition to the clinician’s toolkit.

This new era of neurological understanding and precision treatment, with the integration of technologies like resting-state functional MRI (rs-fMRI) offers clinicians the opportunity to move beyond generalised approaches and provide personalised care.

By harnessing the power of precise, individualised brain function data, clinicians can revolutionise the diagnosis, treatment, and management of neurological disorders, ultimately leading to improved patient outcomes and quality of life.